Can-Fite BioPharma (CANF) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Can-Fite BioPharma’s drug Namodenoson has demonstrated remarkable results in treating advanced liver cancer, with one patient achieving an 8-year survival and complete cure. Currently, the company is enrolling patients in a pivotal Phase III clinical trial for this promising treatment, which has received Orphan Drug and Fast Track designations from both the FDA and EMA. With the global market for liver cancer treatments projected to reach $6.1 billion by 2027, Can-Fite’s innovative approach could significantly impact the market landscape.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
